Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections

Sara A. Buckman, Tamara Krekel, Anouk E. Muller, John E. Mazuski

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Introduction: The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors. Ceftazidime-avibactam is one of the newest such combination antibiotics, which has been released for treatment of complicated intra-abdominal infections in combination with metronidazole. Areas covered: In this drug evaluation manuscript cIAI along with the chemistry, pharmacodynamics, pharmacokinetics, metabolism and clinical study results of ceftazidime-avibactam are reviewed. Expert opinion: The role of ceftazidime-avibactam in combination with metronidazole in the treatment of cIAI is still to be defined. Patients with cIAI known to be infected with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae would be clear candidates for treatment with this agent, as would patients infected with more common types of extended-spectrum β-lactamase producing Gram-negative pathogens if a carbapenem alternative were desired. At present, it is difficult to establish a clear group of patients with cIAI for whom initial empiric therapy with this agent would be warranted.

Original languageEnglish
Pages (from-to)2341-2349
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number17
StatePublished - Nov 21 2016


  • Antibiotic resistance
  • ceftazidime-avibactam
  • complicatedintra-abdominal infections
  • β-lactam-β-lactamase inhibitors


Dive into the research topics of 'Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections'. Together they form a unique fingerprint.

Cite this